Literature DB >> 9350431

Oxidative modification of glutamine synthetase by amyloid beta peptide.

M Y Aksenov1, M V Aksenova, J M Carney, D A Butterfield.   

Abstract

beta-Amyloid peptide (A beta), the main constituent of senile plaques and diffuse amyloid deposits in Alzheimer's diseased brain, was shown to initiate the development of oxidative stress in neuronal cell cultures. Toxic lots of A beta form free radical species in aqueous solution. It was proposed that A beta-derived free radicals can directly damage cell proteins via oxidative modification. Recently we reported that synthetic A beta can interact with glutamine synthetase (GS) and induce inactivation of this enzyme. In the present study we present the evidence that toxic A beta(25-35) induces the oxidation of pure GS in vitro. It was found that inactivation of GS by A beta, as well as the oxidation of GS by metal-catalyzed oxidation system, is accompanied by an increase of protein carbonyl content. As it was reported previously by our laboratory, radicalization of A beta is not iron or peroxide-dependent. Our present observations consistently show that toxic A beta does not need iron or peroxide to oxidize GS. However, treatment of GS with the peptide, iron and peroxide together significantly stimulates the protein carbonyl formation. Here we report also that A beta(25-35) induces carbonyl formation in BSA. Our results demonstrate that beta-peptide, as well as other free radical generators, induces carbonyl formation when brought into contact with different proteins.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9350431     DOI: 10.3109/10715769709065765

Source DB:  PubMed          Journal:  Free Radic Res        ISSN: 1029-2470


  14 in total

1.  The antioxidant vitamin E modulates amyloid beta-peptide-induced creatine kinase activity inhibition and increased protein oxidation: implications for the free radical hypothesis of Alzheimer's disease.

Authors:  S M Yatin; M Aksenov; D A Butterfield
Journal:  Neurochem Res       Date:  1999-03       Impact factor: 3.996

Review 2.  Role of free radicals in the neurodegenerative diseases: therapeutic implications for antioxidant treatment.

Authors:  B Halliwell
Journal:  Drugs Aging       Date:  2001       Impact factor: 3.923

3.  Temporal relations among amyloid beta-peptide-induced free-radical oxidative stress, neuronal toxicity, and neuronal defensive responses.

Authors:  S M Yatin; M Aksenova; M Aksenov; W R Markesbery; T Aulick; D A Butterfield
Journal:  J Mol Neurosci       Date:  1998-12       Impact factor: 3.444

Review 4.  Oxidative stress and β-amyloid protein in Alzheimer's disease.

Authors:  Zhiyou Cai; Bin Zhao; Anna Ratka
Journal:  Neuromolecular Med       Date:  2011-09-08       Impact factor: 3.843

Review 5.  The 2013 SFRBM discovery award: selected discoveries from the butterfield laboratory of oxidative stress and its sequela in brain in cognitive disorders exemplified by Alzheimer disease and chemotherapy induced cognitive impairment.

Authors:  D Allan Butterfield
Journal:  Free Radic Biol Med       Date:  2014-07-01       Impact factor: 7.376

Review 6.  Dopaminergic agonists: possible neurorescue drugs endowed with independent and synergistic multisites of action.

Authors:  Daniela Uberti; Irene Bianchi; Luca Olivari; Giulia Ferrari-Toninelli; Sara A Bonini; Maurizio Memo
Journal:  Neurochem Res       Date:  2007-05-08       Impact factor: 3.996

7.  Impaired synthesis of erythropoietin, glutamine synthetase and metallothionein in the skin of NOD/SCID/gamma(c)(null) and Foxn1 nu/nu mice with misbalanced production of MHC class II complex.

Authors:  L Danielyan; S Verleysdonk; M Buadze; C H Gleiter; G H Buniatian
Journal:  Neurochem Res       Date:  2009-10-14       Impact factor: 3.996

8.  Amyloid beta-peptide (1-40)-mediated oxidative stress in cultured hippocampal neurons. Protein carbonyl formation, CK BB expression, and the level of Cu, Zn, and Mn SOD mRNA.

Authors:  M Y Aksenov; M V Aksenova; W R Markesbery; D A Butterfield
Journal:  J Mol Neurosci       Date:  1998-06       Impact factor: 3.444

Review 9.  The glutamatergic system and Alzheimer's disease: therapeutic implications.

Authors:  D Allan Butterfield; Chava B Pocernich
Journal:  CNS Drugs       Date:  2003       Impact factor: 5.749

10.  The free radical antioxidant vitamin E protects cortical synaptosomal membranes from amyloid beta-peptide(25-35) toxicity but not from hydroxynonenal toxicity: relevance to the free radical hypothesis of Alzheimer's disease.

Authors:  R Subramaniam; T Koppal; M Green; S Yatin; B Jordan; J Drake; D A Butterfield
Journal:  Neurochem Res       Date:  1998-11       Impact factor: 3.996

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.